Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Lim, M. S., Ma, S., Malek, S., Mato, A., Mosse, C., Shadman, M., Siddiqi, T., Stephens, D., Sundaram, S., Wagner, N., Dwyer, M., Sundar, H. 2020; 18 (2): 185–217


Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.

View details for DOI 10.6004/jnccn.2020.0006

View details for Web of Science ID 000512898500010

View details for PubMedID 32023533